BioSpace News Archive

According to Vision Research Reports, the global healthcare staffing market size is expected to be worth around US$ 50 billion by 2030 from valued at US$ 33 billion in 2021 and is anticipated to grow at a CAGR of 5.5% during forecast period 2022 to 2030.

As per Vision Research Reports, the global life sciences BPO market size surpassed at US$ 370 billion in 2021 and is expected to surpass around US$ 850 billion by 2030 with a registered CAGR of 12% from 2022 to 2030.

BioSig Technologies, Inc., a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it intends to offer shares of its common stock in a “best efforts” underwritten public offering.

Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam ® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht.

Novaremed AG announces the simultaneous publication of data from three Phase 1 studies in Clinical Pharmacology in Drug Development and one Phase 2a, placebo-controlled, dose-finding, proof of concept study in European Journal of Pain with the Company’s lead investigational drug candidate NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy.

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced the publication of its multicenter prostate cancer focal therapy study in The Lancet Oncology journal.

Olympus, a global technology leader in designing and delivering innovative medical technology solutions, announced today the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind™ procedure.

Nextleaf has recently produced THC-O under the Company’s Health Canada Research Licence in anticipation of commercialization. Nextleaf has validated its manufacturing process of THC-O through third-party analytical testing.

On June 23, Berry Oncology, a global leading company specialized in genomic testing and early cancer screening, announced the launch of its innovative one-time precision product HIFI Pan-Cancer Screening, which is an early multi-cancer screening product developed based on the company’s proprietary HIFI technology platform.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equity investment announced on June 20, 2022.